Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2024 Earnings Conference Call October 23, 2024 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2024 Third Quarter Conference Call. My name is Ezra and I will be your coordinator today.
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
I am upgrading Thermo Fisher Scientific Inc. to a “Buy” with a fair value of $610 per share due to anticipated recovery in the pharma and biotech industries. Thermo Fisher's high-impact innovations and strategic M&A, including the acquisition of Olink, support a 7%-9% organic revenue growth and mid-teens EPS growth. Q3 results show stabilization in life sciences, with raised full-year adjusted EPS guidance, maintaining revenue guidance of $42.4 to $43.3 billion.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $5.25 per share. This compares to earnings of $5.69 per share a year ago.
Thermo Fisher Scientific on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved demand for its tools and services used in drug development.
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength in Analytical Instrument and Specialty Diagnostics segments is likely to have driven Thermo Fisher's third-quarter 2024 performance.
Thermo Fisher introduces the iCAP MX Series ICP-MS to simplify trace elemental analysis.
Thermo Fisher advances in its growth strategy, supported by its wave of innovations. However, macroeconomic issues escalate expenses.
Thermo Fisher has outperformed the market with a 420%+ return over the past decade, but its current valuation is high. The company's recent results show mixed performance, with slight revenue decline, but improved earnings-per-share and raised 2024 guidance. Despite strong growth prospects and market tailwinds, the stock's high valuation and low dividend yield make it a hold for now.